Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parki
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease - Full Text View - ClinicalTrials.gov
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease (PD Nilotinib) |
Information on recruitment
I note that they say that this Nilotinib-for-PD trial (Phase 2 trial) is scheduled to start in January, and that recruitment has not yet commenced.
I got an email from GU earlier this week. In the email they said that for their Nilotinib trials they will only be recruiting patients who live within 50 miles of Georgetown University Hospital in Washington DC. |
All times are GMT -5. The time now is 09:55 AM. |
Powered by vBulletin Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise v2.7.1 (Lite) -
vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.